Company / Operating Cash Flow per Share
Jade Biosciences, Inc. Operating Cash Flow per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.49
FY2024
5-year range
-$32.44 / -$1.60
FY2020-FY2024
Trend
-15.5%
vs FY2023
Sector context
#160 of 208
Health Care
What the data says
Jade Biosciences, Inc.'s operating cash flow per share of $-2.49 is lower than 77% of companies in the Health Care sector (FY2024). Declined from $-1.60 to $-2.49 over the past 2 years.
Based on SEC 10-K filings.
-2.49 in FY2024.
Declined from $-1.60 to $-2.49 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 208This company -$2.49 Sector average -$21.21
▼
+88.3% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share decreased 15.5% year-over-year.
- Ranks #160 out of 208 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2022.
- Lowest operating cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.03 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.49 | -15.5% |
| FY2023 | -$2.16 | -34.9% |
| FY2022 | -$1.60 | +28.3% |
| FY2021 | -$2.23 | +93.1% |
| FY2020 | -$32.44 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026